drugset / Trial / NCT07099391
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).
Timeline
- Start
- 2025-07-24
- Primary completion
- 2029-07-24
- Completion
- 2029-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Teclistamab | Monoclonal antibody | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |